To date, the three FDA-approved CDK4/6i abemaciclib, palbociclib, and ribociclib are a front-line treatment in combination with hormonal therapy for metastatic HR+-HER2− breast cancer (BC)9,10. The gene discussed is CDK4; the disease is breast cancer.